Search
forLearn
5 / 801 resultslearn Snapdragon
learn TDM-105795
learn Selenium AAC
learn RH410
Research
5 / 200 results
research Establishment and characterization of five immortalized human scalp dermal papilla cell lines
Researchers created five new human scalp cell lines that could be useful for hair growth and loss research.
research Establishment and characterization of matched immortalized human frontal and occipital scalp dermal papilla cell lines from androgenetic alopecia
Scientists created cell lines from balding patients and found that cells from the front of the scalp are more affected by hormones that cause hair loss than those from the back.
research Establishment and Functional Characterization of Immortalized Rabbit Dermal Papilla Cell Lines
Researchers created a stable rabbit cell line for hair research that doesn't age quickly or become cancerous.
research Establishment of keratinocyte cell lines from human hair follicles
Scientists created keratinocyte cell lines from human hair that can differentiate similarly to normal skin cells, offering a new way to study skin biology and diseases.
research Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
LGD1069 effectively prevents breast tumors in mice without toxicity.
Community Join
5 / 1000+ resultscommunity ASATONA AG and "Asatex"
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
community RU55481
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community NW5 advice current treatments AGA
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.